FOLFIRINOX regimen

DRUG3 trials

Sponsors

Baylor Research Institute, Seoul National University Hospital, Zhejiang Provincial People's Hospital

Conditions

Chemotherapy EffectLDRTLocalized Pancreas CancerNon-metastatic Pancreas CancerPD-1 InhibitorPD-L1Pancreas CancerPancreatic Cancer

Phase 1

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

RecruitingNCT07312422

Zhejiang Provincial People's HospitalLDRT, Pancreatic Cancer, PD-1 Inhibitor +2

Start: 2025-09-30End: 2026-10-30Target: 10Updated: 2026-01-26

Unknown Phase

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

Baylor Research InstituteLocalized Pancreas Cancer, Non-metastatic Pancreas Cancer, Pancreas Cancer

Start: 2012-10-31End: 2020-09-30Target: 30Updated: 2017-01-31

Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer

Seoul National University HospitalChemotherapy Effect, Pancreatic Cancer Non-resectable, Ultrasound Therapy

Start: 2021-08-09End: 2024-12-31Target: 60Updated: 2022-10-26

Related Papers

FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.

Journal of Clinical Oncology2024-01-20